Advertisement
UK markets close in 21 minutes

  • FTSE 100

    7,815.78
    -149.75 (-1.88%)
     

  • FTSE 250

    19,355.89
    -343.00 (-1.74%)
     

  • AIM

    739.42
    -10.86 (-1.45%)
     

  • GBP/EUR

    1.1698
    -0.0012 (-0.11%)
     

  • GBP/USD

    1.2445
    -0.0002 (-0.01%)
     

  • Bitcoin GBP

    50,060.16
    -1,686.47 (-3.26%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,053.65
    -8.17 (-0.16%)
     

  • DOW

    37,815.43
    +80.32 (+0.21%)
     

  • CRUDE OIL

    85.61
    +0.20 (+0.23%)
     

  • GOLD FUTURES

    2,398.20
    +15.20 (+0.64%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,737.83
    -288.75 (-1.60%)
     

  • CAC 40

    7,918.50
    -126.61 (-1.57%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Should You Buy Genmab (GMAB) Ahead of Earnings?

Zacks Equity Research
·2-min read

Investors are always looking for stocks that are poised to beat at earnings season and Genmab GMAB may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Genmab is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for GMAB in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 14 cents per share for GMAB, compared to a broader Zacks Consensus Estimate of 10 cents per share. This suggests that analysts have very recently bumped up their estimates for GMAB, giving the stock a Zacks Earnings ESP of +30.41% heading into earnings season.

Genmab AS Sponsored ADR Price and EPS Surprise

Genmab AS Sponsored ADR price-eps-surprise | Genmab AS Sponsored ADR Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that GMAB has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Genmab, and that a beat might be in the cards for the upcoming report.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Genmab AS Sponsored ADR (GMAB) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research